CStone Pharmaceuticals
CSPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $24,726 | $153,040 | $254,165 | $202,368 |
| % Growth | -83.8% | -39.8% | 25.6% | – |
| Cost of Goods Sold | $71,121 | $84,915 | $82,136 | $51,510 |
| Gross Profit | -$46,395 | $68,125 | $172,029 | $150,858 |
| % Margin | -187.6% | 44.5% | 67.7% | 74.5% |
| R&D Expenses | $52,583 | $68,409 | $66,248 | $341,029 |
| G&A Expenses | $21,531 | $28,724 | $45,172 | $91,504 |
| SG&A Expenses | $39,600 | $102,139 | $109,441 | $161,429 |
| Sales & Mktg Exp. | $17,827 | $71,009 | $62,769 | $67,904 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $92,183 | $170,548 | $175,689 | $407,439 |
| Operating Income | -$138,578 | -$102,423 | -$3,660 | -$351,600 |
| % Margin | -560.5% | -66.9% | -1.4% | -173.7% |
| Other Income/Exp. Net | $3,487 | -$4,483 | $19,359 | $193,592 |
| Pre-Tax Income | -$135,092 | -$106,906 | $15,699 | -$158,008 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$135,092 | -$106,906 | $15,699 | -$158,008 |
| % Margin | -546.4% | -69.9% | 6.2% | -78.1% |
| EPS | -0.1 | -0.084 | 0.01 | -0.124 |
| % Growth | -19.3% | -938% | 108.1% | – |
| EPS Diluted | -0.1 | -0.084 | 0.012 | -0.124 |
| Weighted Avg Shares Out | 1,286,586 | 1,276,886 | 1,569,900 | 1,274,361 |
| Weighted Avg Shares Out Dil | 1,314,139 | 1,276,884 | 1,275,512 | 1,274,353 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $15,373 |
| Interest Expense | $2,911 | $1,590 | $0 | $0 |
| Depreciation & Amortization | $3,324 | $6,414 | $6,882 | $9,219 |
| EBITDA | -$133,103 | -$85,282 | $3,222 | -$342,381 |
| % Margin | -538.3% | -55.7% | 1.3% | -169.2% |